Yoshihiko Fukukura1, Yuichi Kumagae2, Ryutaro Higashi2, Hiroto Hakamada2, Koji Takumi2, Kosei Maemura3, Michiyo Higashi4, Kiyohisa Kamimura2, Masanori Nakajo2, Takashi Yoshiura2. 1. Department of Radiology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima City, 890-8544, Japan. fukukura@m.kufm.kagoshima-u.ac.jp. 2. Department of Radiology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima City, 890-8544, Japan. 3. Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima City, 890-8544, Japan. 4. Human Pathology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima City, 890-8544, Japan.
Abstract
OBJECTIVES: To assess whether extracellular volume (ECV) fraction with equilibrium contrast-enhanced multidetector computed tomography (MDCT) predicts outcomes for unresectable pancreatic adenocarcinoma patients treated with chemotherapy METHODS: Sixty-seven patients (42 men, 25 women; mean age, 67.5 years; range, 45-83 years) with histologically confirmed surgically unresectable pancreatic adenocarcinoma underwent contrast-enhanced MDCT before systemic chemotherapy. Tumour contrast enhancement (CE) and ECV fraction were calculated using region-of-interest measurement within the pancreatic adenocarcinoma and aorta on unenhanced and equilibrium phase-enhanced CT. The effect on survival variables including age, sex, tumour location, tumour size, TNM stage, carbohydrate antigen (CA) 19-9, carcinoembryonic antigen (CEA), tumour CE and tumour ECV fraction was determined on univariate and multivariate analyses using Cox proportional hazards regression model. RESULTS: Median overall survival was 10.5 months. On univariate analysis, elevated serum CA19-9 (hazard ratio (HR), 1.00; p = 0.006) and CEA (HR, 1.02; p = 0.011) levels were found to be associated with a negative effect on overall survival. Increasing tumour CE (HR, 0.98; p < 0.001) and ECV fraction (HR, 0.97; p = 0.001) were associated with a positive effect. Multivariate analysis revealed that only tumour ECV fraction was an independent predictor of overall survival (HR, 0.97; p = 0.012). CONCLUSIONS: ECV fraction with equilibrium contrast-enhanced MDCT could be a useful imaging biomarker for predicting patient survival after chemotherapy for unresectable pancreatic adenocarcinoma. KEY POINTS: • Tumour aggressiveness and response to therapy are influenced by the extravascular extracellular space. • Extracellular volume (ECV) fraction can be quantified with equilibrium contrast-enhanced CT. • Patients with higher tumour ECV fraction had better prognosis after chemotherapy.
OBJECTIVES: To assess whether extracellular volume (ECV) fraction with equilibrium contrast-enhanced multidetector computed tomography (MDCT) predicts outcomes for unresectable pancreatic adenocarcinomapatients treated with chemotherapy METHODS: Sixty-seven patients (42 men, 25 women; mean age, 67.5 years; range, 45-83 years) with histologically confirmed surgically unresectable pancreatic adenocarcinoma underwent contrast-enhanced MDCT before systemic chemotherapy. Tumour contrast enhancement (CE) and ECV fraction were calculated using region-of-interest measurement within the pancreatic adenocarcinoma and aorta on unenhanced and equilibrium phase-enhanced CT. The effect on survival variables including age, sex, tumour location, tumour size, TNM stage, carbohydrate antigen (CA) 19-9, carcinoembryonic antigen (CEA), tumour CE and tumour ECV fraction was determined on univariate and multivariate analyses using Cox proportional hazards regression model. RESULTS: Median overall survival was 10.5 months. On univariate analysis, elevated serum CA19-9 (hazard ratio (HR), 1.00; p = 0.006) and CEA (HR, 1.02; p = 0.011) levels were found to be associated with a negative effect on overall survival. Increasing tumour CE (HR, 0.98; p < 0.001) and ECV fraction (HR, 0.97; p = 0.001) were associated with a positive effect. Multivariate analysis revealed that only tumour ECV fraction was an independent predictor of overall survival (HR, 0.97; p = 0.012). CONCLUSIONS: ECV fraction with equilibrium contrast-enhanced MDCT could be a useful imaging biomarker for predicting patient survival after chemotherapy for unresectable pancreatic adenocarcinoma. KEY POINTS: • Tumour aggressiveness and response to therapy are influenced by the extravascular extracellular space. • Extracellular volume (ECV) fraction can be quantified with equilibrium contrast-enhanced CT. • Patients with higher tumour ECV fraction had better prognosis after chemotherapy.
Authors: James L Tatum; Gary J Kelloff; Robert J Gillies; Jeffrey M Arbeit; J Martin Brown; K S Clifford Chao; J Donald Chapman; William C Eckelman; Anthony W Fyles; Amato J Giaccia; Richard P Hill; Cameron J Koch; Murali Cherukuri Krishna; Kenneth A Krohn; Jason S Lewis; Ralph P Mason; Giovanni Melillo; Anwar R Padhani; Garth Powis; Joseph G Rajendran; Richard Reba; Simon P Robinson; Gregg L Semenza; Harold M Swartz; Peter Vaupel; David Yang; Barbara Croft; John Hoffman; Guoying Liu; Helen Stone; Daniel Sullivan Journal: Int J Radiat Biol Date: 2006-10 Impact factor: 2.694
Authors: Claus Koelblinger; Ahmed Ba-Ssalamah; Peter Goetzinger; Stefan Puchner; Michael Weber; Klaus Sahora; Martina Scharitzer; Christina Plank; Wolfgang Schima Journal: Radiology Date: 2011-03-24 Impact factor: 11.105
Authors: A Couvelard; D O'Toole; R Leek; H Turley; A Sauvanet; C Degott; P Ruszniewski; J Belghiti; A L Harris; K Gatter; F Pezzella Journal: Histopathology Date: 2005-06 Impact factor: 5.087
Authors: Steve Bandula; Sanjay M Banypersad; Daniel Sado; Andrew S Flett; Shonit Punwani; Stuart A Taylor; Philip N Hawkins; James C Moon Journal: Radiology Date: 2013-05-14 Impact factor: 11.105
Authors: Maurice H Zissen; Zhen Jane Wang; Judy Yee; Rizwan Aslam; Alexander Monto; Benjamin M Yeh Journal: AJR Am J Roentgenol Date: 2013-12 Impact factor: 3.959
Authors: Sanjay M Banypersad; Daniel M Sado; Andrew S Flett; Simon D J Gibbs; Jennifer H Pinney; Viviana Maestrini; Andrew T Cox; Marianna Fontana; Carol J Whelan; Ashutosh D Wechalekar; Philip N Hawkins; James C Moon Journal: Circ Cardiovasc Imaging Date: 2012-11-28 Impact factor: 7.792